Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 8/20 | 0.42 |
| ▸ | PPARG | P37231 | 8/20 | 0.42 |
| ▸ | TNFRSF1A | P19438 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6093024 | 0.90 | PPARG (0.42) | PPARAPPARGTNFRSF1AERN1PPARD | |
| SCHEMBL6092104 | 0.89 | PPARA (0.42) | PPARAPPARGTNFRSF1ATSHRMAPK1 | |
| SCHEMBL6094282 | 0.83 | TNFRSF1A (0.44) | TNFRSF1ATSHRMAPK1SMN1; SMN2ERN1 | |
| SCHEMBL6093492 | 0.83 | ERN1 (0.43) | PPARATNFRSF1ATSHRMAPK1SMN1; SMN2 | |
| SCHEMBL6091494 | 0.82 | TNFRSF1A (0.44) | PPARAPPARGTNFRSF1AERN1KDM4E | |
| SCHEMBL6090983 | 0.81 | TNFRSF1A (0.47) | PPARGTNFRSF1ASMN1; SMN2ERN1KDM4E | |
| SCHEMBL6109489 | 0.81 | TNFRSF1A (0.50) | PPARAPPARGTNFRSF1AMAPK1KDM4E | |
| SCHEMBL6094177 | 0.81 | MAPT (0.48) | TSHRMAPK1SMN1; SMN2ERN1KDM4E | |
| SCHEMBL6092948 | 0.79 | PPARA (0.46) | PPARAPPARGTNFRSF1ATSHRSMN1; SMN2 | |
| SCHEMBL6092987 | 0.79 | ERN1 (0.46) | TNFRSF1AERN1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ATHEROGENICS, INC. | 2006-03-23 | — | — | US | disclosed |
| WO-2006004903-A2 | 1,2-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ATHEROGENICS, INC. (US) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ABCB11, CEL, CYP46A1 | PPARA 457/4885PPARG 535/4885TNFRSF1A 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.